Adenosine deaminase deficiency as the first target disorder in gene therapy

Bibliography

• MULLIGAN RC: The basic science of gene therapy.Science (1993) 260:926–932.
   PubMed Web of Science ®Google Scholar
• JOYNER A, KELLER G, PHILLIPS RA, BERNSTEIN A:Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature (1983) 305:556–558.
   PubMed Web of Science ®Google Scholar
• •The first report of successful gene transfer into murine HSCs.
   Google Scholar
• BLAESE RM, CULVER KW, MILLER AD et al.: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science (1995) 270:475–480.
   PubMed Web of Science ®Google Scholar
• ••Historical report of the first gene therapy for humandiseases.
   Google Scholar
• DUNBAR CE, COTTLER-FOX M, O'SHAUGHNESSY JA et al.:Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood (1995) 85:3048–3057.
   Google Scholar
• MALECH HL, MAPLES PB, WHITING-THEOBALD N et al.:Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulo-matous disease. Proc. Natl. Acad. Sci. USA (1997) 94:12133–12138.
   PubMed Web of Science ®Google Scholar
• LIU JM, KIM S, READ EJ et al.: Engraftment of hemato-poietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum. Gene Ther. (1999) 10:2337–2346.
   PubMed Web of Science ®Google Scholar
• HERSHFIELD MS, MITCHELL BS: Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS et al. (Eds.), McGraw Hill, New York, USA (1995):1725–1768.
   Google Scholar
• CHOTTINER EG, SHEWACH DS, DATTA NS et al.: Cloning and expression of human deoxycytidine kinase cDNA. Proc. Natl. Acad. Sci. USA (1991) 15:1531–1535.
   Google Scholar
• HERSHFIELD MS, KREDICH NM: Resistance of anadenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosyl homocysteine hydrolase inactivation, and dATP accumulation. Proc. Natl. Acad. Sci. USA (1980) 77:4292–4296.
   PubMed Web of Science ®Google Scholar
• HIRSCHHORN R, ELLENBOGEN A: Genetic heteroge-neity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency. Am. J. Hum. Genet. (1986) 38:13–25.
   PubMed Web of Science ®Google Scholar
• MORGAN G, LEVINSKY RJ, HUGH-JONES K, FAIRBANKSLD, MORRIS GS, SIMMONDS HA: Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin. Exp. Immunol. (1987) 70:491–499.
   PubMed Web of Science ®Google Scholar
• HIRSCHHORN R: Overview of biochemical abnormali-ties and molecular genetics of adenosine deaminase deficiency. Pediatr. Res. (1993) 33 (Suppl. 1):S35–S41.
   Google Scholar
• •Good review of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency.
   Google Scholar
• KAPOOR N, CROOKS G, KOHN DB, PARKMAN R: Hematopoietic stem cell transplantation for primary lymphoid immunodeficiencies. Semin. Hematol (1998) 35:346–353.
   PubMed Web of Science ®Google Scholar
• POLMAR SH, STERN RC, SCHWARTZ AL, WETZLER EM, CHASE PA, HIRSCHHORN R: Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl. J. Med. (1976) 295:1337–1343.
   PubMed Web of Science ®Google Scholar
• HERSHFIELD MS, BUCKLEY RH, GREENBERG ML et al: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl. J. Med. (1987) 316:589–596.
   PubMed Web of Science ®Google Scholar
• •Important paper discussing the effectiveness of PEG-ADA treatment on patients with ADA-SCID.
   Google Scholar
• HERSHFIELD MS: Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin. Hematol (1998) 35:291–298.
   PubMed Web of Science ®Google Scholar
• DADDONA PE, SHEWACH DS, KELLEY WN, ARGOS P, MARKHAM AF, ORKIN SH: Human adenosine deaminase. cDNA and complete primary amino acid sequence. Clin. Exp. Immunol. (1984) 259:12101–12106.
   Google Scholar
• VALERIO D, MCIVOR RS, WILLIAMS SR et al.: Cloning of human adenosine deaminase cDNA and expression in mouse cells. Gene (1984) 31:147–153.
   PubMed Web of Science ®Google Scholar
• WIGINTON DA, ADRIAN GS, HUTTON JJ: Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acids Res. (1984) 12:2439–2446.
   PubMed Web of Science ®Google Scholar
• WIGINTON DA, KAPLAN DJ, STATES JC et al.: Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry (1986) 25:8234–8244.
   PubMed Web of Science ®Google Scholar
• DADDONA PE, MITCHELL BS, MEUWISSEN HJ, DAVIDSON BL, WILSON JM, KOLLER CA: Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. J. Clin. Invest. (1983) 72:483–492.
   PubMed Web of Science ®Google Scholar
• VALENTINE WN, PAGLIA DE, TARTAGLIA AP, GILSANZ F: Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science (1977) 195:783–785.
   PubMed Web of Science ®Google Scholar
• FERRARI G, ROSSINI S, GIAVAZZI R et al: An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science (1 9 9 1) 251:1363-1366.
   Google Scholar
• VAN BEUSECHEM VW, KUKLER A, EINERHAND MP et al.:Expression of human adenosine deaminase in mice transplanted with hematopoietic stem cells infected with amphotropic retroviruses. J. Exp. Med. (1990) 172:729–736.
   PubMed Web of Science ®Google Scholar
• LIM B, APPERLEY JF, ORKIN SH, WILLIAMS DA: Long-termexpression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc. Natl. Acad. Sci. USA (1989) 86:8892–8896.
   PubMed Web of Science ®Google Scholar
• KANTOFF PW, GILLIO AP, MCLACHLIN JR et al.: Expres-sion of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J. Exp. Med. (1987) 166:219–234.
   PubMed Web of Science ®Google Scholar
• BUCKLEY RH, SCHIFF SE, SAMPSON HA et al.: Develop-ment of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J. Immunol. (1 98 6) 136:2398-2407.
   Google Scholar
• CULVER KW, MORGAN RA, OSBORNE WR et al.: In vivoexpression and survival of gene-modified T lympho-cytes in rhesus monkeys. Hum. Gene Ther. (1990) 1:399–410.
   PubMed Web of Science ®Google Scholar
• ONODERA M, ARIGA T, KAWAMURA N et al.: Successfulperipheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood (1998) 91:30–36.
   PubMed Web of Science ®Google Scholar
• BORDIGNON C, NOTARANGELO LD, NOBILI N et al.: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 270:470–475.
   PubMed Web of Science ®Google Scholar
• ••Historical report of the first gene therapy for humandiseases.
   Google Scholar
• HOOGERBRUGGE PM, VAN BEUSECHEM VW, FISCHER Aet al.: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. (1996) 3:179–183.
   Google Scholar
• KOHN DB, WEINBERG KI, NOLTA JA et al.: Engraftmentof gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. (1995) 1:1017–1023.
   PubMed Web of Science ®Google Scholar
• •First report showing the possibility of cord blood as a target population in stem cell gene therapy.
   Google Scholar
• KOHN DB, HERSHFIELD MS, CARBONARO D et al.: Tlymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nature Med. (1998) 4:775–780.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, ELLIOTT M, LEWINSOHN DA et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. (1996) 2: 216–223.
   PubMed Web of Science ®Google Scholar
• ••Paper showing important data relating to the immuneresponse against the selectable markers derived from the non-human origin.
   Google Scholar
• W PIACIBELLO, F SANAVIO, A SEVERINO et al: Engraft-ment in nonobese diabetic severe combined immuno-deficient mice of human CD34+ cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood (1999) 93:3736–3749.
   PubMed Web of Science ®Google Scholar
• HANENBERG H, XIAO XL, DILLOO D, HASHINO K, KATO I, WILLIAMS DA: Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med. (1996) 2:876–882.
   PubMed Web of Science ®Google Scholar
• •Important paper showing the efficacy of fibronectin on increase of the transduction frequencies in human CD34+ cells.
   Google Scholar
• KIEM HP, ANDREWS RG, MORRIS J et al: Improved genetransfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood (1998) 92: 1878-1886.
   Google Scholar
• HUHN RD, TISDALE JF, AGRICOLA B, METZGER ME, DONAHUE RE, DUNBAR CE: Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum. Gene Ther. (1999) 10:1783–1790.
   PubMed Web of Science ®Google Scholar
• ONODERA M, NELSON DM, YACHIE A et al.: Develop-ment of improved adenosine deaminase retroviral vectors. J. Virol (1998) 72:1769–1774.
   PubMed Web of Science ®Google Scholar
• ONODERA M, NELSON DM, SAKIYAMA Y, CANDOTTI F,BLAESE RM: Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Acta Haematol (1999) 101:89–96.
   PubMed Web of Science ®Google Scholar
• MIYOSHI H, SMITH KA, MOSIER DE, VERMA IM, TORBETTBE: Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 283:682–686.
   PubMed Web of Science ®Google Scholar
• •Paper demonstrating the feasibility of lenti-vectors as a potential vector for stem cell gene therapy by using the SRC assay.
   Google Scholar